Moderna Teams With Korea University to Develop Revolutionary Hantavirus Vaccine

Breakthrough Partnership Targets Deadly Virus

A groundbreaking collaboration between pharmaceutical giant Moderna and Korea University's Vaccine Innovation Center is racing to develop the world's first mRNA-based hantavirus vaccine. The partnership, which began with a research agreement signed in September 2023, has already shown promising results with experimental doses preventing hantavirus infection in mice studies confirmed in February 2025 .

The World Health Organization has designated hantavirus as a potential "Disease X" pathogen capable of triggering new infectious diseases , making this vaccine development effort particularly urgent. Korea reports 300 to 400 cases of hantavirus-induced hemorrhagic fever annually, with the disease particularly affecting young men in their 20s and 30s during military service .

Advanced Technology Promises Broader Protection

This collaboration operates under Moderna's mRNA Access initiative, a program that supplies preclinical mRNA vaccine candidates to academic teams working on emerging or neglected infectious diseases . The Korean team has provided Moderna with detailed hantavirus antigen sequences, while Moderna supplies corresponding mRNA materials for testing.

The current Korean vaccine, Hantavax, has been available since 1990 but offers limited long-term protection and does not cover hantavirus pulmonary syndrome strains found in Western countries . The new mRNA vaccine aims to be effective against a wider range of virus strains compared to existing vaccines , potentially offering global protection rather than regional coverage.

From Laboratory Success to Human Trials

The scientific foundation for this vaccine builds on decades of research. Korea University has deep expertise in hantavirus research, continuing the legacy of Professor Lee Ho-wang, who first isolated the virus in 1976 . Recent laboratory work has demonstrated the vaccine's effectiveness in animal models, with researchers conducting successful antigen expression studies.

The vaccine candidate is now awaiting funding to begin human clinical trials . The project has received significant support, including a 10 billion won (€6.5 million) donation from Hyundai Motor Group Honorary Chairman Chung Mong-koo , demonstrating strong commitment to advancing this critical public health initiative.

Global Health Impact on the Horizon

The timing of this vaccine development has gained renewed attention following recent hantavirus outbreaks, including cases linked to cruise ships. Hantavirus infections remain uncommon in the United States, with only 890 cases reported between 1993 and 2023, typically spread through exposure to infected rodent droppings or saliva .

However, the virus's potential for severe outcomes makes prevention crucial. Hantavirus causes severe Hantavirus Pulmonary Syndrome with a fatality rate exceeding 30% , underscoring the urgent need for effective vaccines. If successful, this mRNA approach could provide a template for rapidly developing vaccines against other emerging infectious diseases, potentially transforming how the world prepares for future pandemic threats.